Lamdong Pharmaceutical JSC (HNX:LDP)
Vietnam · Delayed Price · Currency is VND 7,800.00
-100.00 (-1.27%)
At close: May 15, 2026
HNX:LDP Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 242,875 | 243,906 | 217,958 | 186,001 | 187,415 | 161,902 | |
Revenue Growth (YoY) | 4.00% | 11.91% | 17.18% | -0.75% | 15.76% | -57.36% |
Cost of Revenue | 160,462 | 162,674 | 153,567 | 148,835 | 149,895 | 140,678 |
Gross Profit | 82,413 | 81,232 | 64,390 | 37,166 | 37,519 | 21,225 |
Selling, General & Admin | 65,142 | 63,772 | 51,110 | 49,512 | 62,833 | 41,013 |
Operating Expenses | 65,142 | 63,772 | 51,110 | 49,512 | 62,833 | 41,013 |
Operating Income | 17,271 | 17,460 | 13,280 | -12,347 | -25,314 | -19,788 |
Interest Expense | -3,760 | -4,160 | -4,979 | -7,027 | -7,544 | -2,210 |
Interest & Investment Income | 421.86 | 355.34 | 281.55 | 775.36 | 2,862 | 31,615 |
Other Non Operating Income (Expenses) | 1,007 | 1,007 | -1,728 | 21.67 | -8,851 | 31,105 |
EBT Excluding Unusual Items | 14,940 | 14,662 | 6,855 | -18,576 | -38,848 | 40,721 |
Gain (Loss) on Sale of Investments | - | - | - | -634.63 | - | - |
Gain (Loss) on Sale of Assets | 14,239 | 14,039 | 63.64 | -894.01 | - | - |
Pretax Income | 29,179 | 28,700 | 6,919 | -20,105 | -38,848 | 40,721 |
Income Tax Expense | 700.32 | 142.63 | - | - | 43.69 | 2,850 |
Net Income | 28,479 | 28,558 | 6,919 | -20,105 | -38,891 | 37,870 |
Net Income to Common | 28,479 | 28,558 | 6,919 | -20,105 | -38,891 | 37,870 |
Net Income Growth | 267.20% | 312.75% | - | - | - | 295.07% |
Shares Outstanding (Basic) | 16 | 14 | 13 | 13 | 13 | 13 |
Shares Outstanding (Diluted) | 16 | 14 | 13 | 13 | 13 | 13 |
Shares Change (YoY) | 22.64% | 10.75% | - | 0.01% | -0.02% | 62.22% |
EPS (Basic) | 1828.33 | 2029.81 | 544.66 | -1582.67 | -3062.00 | 2981.00 |
EPS (Diluted) | 1828.33 | 2029.81 | 544.66 | -1583.00 | -3062.00 | 2981.00 |
EPS Growth | 199.41% | 272.67% | - | - | - | 143.55% |
Free Cash Flow | -58,831 | -59,594 | 5,835 | 5,977 | -46,718 | 21,392 |
Free Cash Flow Per Share | -3776.93 | -4235.81 | 459.36 | 470.51 | -3678.26 | 1683.88 |
Gross Margin | 33.93% | 33.30% | 29.54% | 19.98% | 20.02% | 13.11% |
Operating Margin | 7.11% | 7.16% | 6.09% | -6.64% | -13.51% | -12.22% |
Profit Margin | 11.73% | 11.71% | 3.17% | -10.81% | -20.75% | 23.39% |
Free Cash Flow Margin | -24.22% | -24.43% | 2.68% | 3.21% | -24.93% | 13.21% |
EBITDA | 22,482 | 23,115 | 20,244 | -4,110 | -16,414 | -8,047 |
EBITDA Margin | 9.26% | 9.48% | 9.29% | -2.21% | -8.76% | -4.97% |
D&A For EBITDA | 5,210 | 5,655 | 6,964 | 8,237 | 8,900 | 11,742 |
EBIT | 17,271 | 17,460 | 13,280 | -12,347 | -25,314 | -19,788 |
EBIT Margin | 7.11% | 7.16% | 6.09% | -6.64% | -13.51% | -12.22% |
Effective Tax Rate | 2.40% | 0.50% | - | - | - | 7.00% |
Revenue as Reported | 242,875 | 243,906 | 217,958 | 186,001 | 187,415 | 161,902 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.